See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Holi
Natural Disasters
Social Media
Baseball
Artificial Intelligence
Vladimir Putin
Senate
Basketball
Stock Markets
Donald Trump
Soccer
Boxing
Published • loading... • Updated

The TCR-T cell therapies of tomorrow - Beyond Biotech - the podcast from Labiotech

Summary by Labiotech.eu
Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with TCR-T cell therapy trials. The post The TCR-T cell therapies of tomorrow appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Labiotech.euLabiotech.eu

The TCR-T cell therapies of tomorrow - Beyond Biotech - the podcast from Labiotech

Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with TCR-T cell therapy trials. The post The TCR-T cell therapies of tomorrow appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that…

Read Full Article
Mittelstand CafeMittelstand Cafe

Medigene and EpimAb Biotherapeutics conclude co-development partnership for TCR-controlled T-cell-engager - Mittelstand Cafe

Planegg/Martinsried, February 27, 2025 / IRW-Press / Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb) today announced the conclusion of a strategic joint development agreement. The aim of the partnership is the research and development of "off-the-shelf" T-cell receptor (TCR)-controlled T-cell receptors (TCR-TCEs) for the treatment of immune-related diseases, especially solid tumours.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Mittelstand Cafe broke the news in on Thursday, February 27, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Bavaria

Bavaria

Sweden

Sweden

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal